Since the induction of MDR-1 expression by EGF has been reported in breast cancer cells [27], and EGFR expression is induced as a consequence of β1 integrin ligation [28], we hypothesized that FNIII14-mediated inactivation of β1 integrin might impact cellular drug efflux capacity. The gene discussed is EGF; the disease is breast carcinoma.